...
首页> 外文期刊>Journal of Surgical Oncology >Clinical significance of combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma.
【24h】

Clinical significance of combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma.

机译:凋亡因子与增殖细胞核抗原联合研究在评估肝细胞癌预后中的临床意义。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND AND OBJECTIVES: Hepatocellular carcinoma (HCC) is one of the most common recurrence diseases, which affects the patient's prognosis. The aim of this report is to evaluate recurrence risk after primary treatment by the combination study with the clinical features and immunohistological findings. METHODS: 153 removable HCCs were examined by immunohistochemical study of the proliferating cell nuclear antigen (PCNA), p53, or Bax. The relationships of these factors with histological grades, the presence of intra-hepatic metastasis (IM), tumor size, value of serum alpha-fetoprotein (AFP), and prognosis were studied. PCNA labeling index (LI) was calculated to count positive nuclei in 1,000 cells. RESULTS: PCNALI was significantly higher in cancer and correlated with tumor size. PCNALI and the tumor diameter in themselves could be a good predictor for patient prognosis and the combination study of them was an even stronger indicator. The value of AFP was significantly higher in positive p53 cases. The incidence of p53 was associated with histological types. The presence of IM was found in negative Bax cases of main tumors. The appearance of Bax was not correlated with histological types. The incidence of p53 or Bax was indicated to distinguish the patient prognosis of the lower grade histological cases, in which differences could not be found by the routine histological study. CONCLUSIONS: The combination study of the immunohistochemical findings and the clinical features could be one of the most important aids in interpreting the status of HCC.
机译:背景与目的:肝细胞癌(HCC)是最常见的复发性疾病之一,它会影响患者的预后。本报告的目的是通过结合临床特征和免疫组织学发现的联合研究来评估初次治疗后的复发风险。方法:通过免疫组织化学研究,对153例可切除的HCCs进行了增殖细胞核抗原(PCNA),p53或Bax的检测。研究了这些因素与组织学等级,肝内转移(IM)的存在,肿瘤大小,血清甲胎蛋白(AFP)值和预后的关系。计算PCNA标记指数(LI)以计数1,000个细胞中的阳性细胞核。结果:PCNALI在癌症中显着升高,并与肿瘤大小相关。 PCNALI和肿瘤直径本身可以很好地预测患者的预后,将它们结合起来研究甚至可以更有效地指示患者。在p53阳性的病例中,AFP的值明显更高。 p53的发生与组织学类型有关。在主要肿瘤的阴性Bax病例中发现了IM的存在。 Bax的出现与组织学类型无关。 p53或Bax的发生率可用来区分低度组织学病例的患者预后,在常规组织学研究中无法发现差异。结论:免疫组化结果与临床特征的结合研究可能是解释肝癌状态的最重要手段之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号